Editor: Jianxun Song

Series Title: Frontiers in Cancer Immunology

Cancer Immunotherapy: Mechanisms of Cancer Immunity, Engineering Immune-Based Therapies and Developing Clinical Trials

Volume 1

eBook: US $99 Special Offer (PDF + Printed Copy): US $178
Printed Copy: US $129
Library License: US $396
ISSN: 2405-9102 (Print)
ISSN: 2405-9110 (Online)
ISBN: 978-1-68108-049-9 (Print)
ISBN: 978-1-68108-048-2 (Online)
Year of Publication: 2015


Clinicians, patients and scientists, alike, have been battling cancer for over several decades; however, patient outcomes have not significantly improved over the years with conventional therapies. In recent years, this has caused researchers to look for a change in the status quo, and, the awareness of the human immune system, which has an intrinsic mechanism to control microbial pathogens and dysfunctional self-tissues, has triggered scientists to look for new modes of cancer therapy. Cancer Immunotherapy has become a major research field as a result of these efforts, gaining some recognition for notable breakthroughs in cancer patient prognosis. Frontiers in Cancer Immunology collectively presents the methods which have been studied and used in cancer immunotherapy based on the different components of human immune system. The series will give clinicians and immunologists a roadmap of current trends in all branches of cancer immunology. This volume lists the major immune system components (such as T cells and NK cells and associated antigens/antibodies) which have been demonstrated to limit the growth of or kill tumor cells. Relevant applications in cancer therapy are also included in addition to a general introduction to engineered as well as targeted cancer immunotherapies (cancer vaccines).


It is a privilege to write the Foreword for this book which is an outstanding review of cutting edge cancer immunotherapy. Despite early promises in some cancers, immunotherapy had generally failed to achieve consistent success. This scenario has changed drastically in the past few years. Indeed, Science Magazine hailed the advances in cancer immunotherapy as the number one breakthrough in all scientific disciplines for 2013.

The chapters of the book encompass all the different aspects of cancer immunotherapy and are authored by worldwide authorities in this field. There is a nice introductory chapter by the editor J. Song who provides a broad overview of the field. All chapters have a focus on clinical application and translational medicine. Individual chapters discuss the basic immunology of cytotoxic T cells, NK cells, dendritic cells, and regulatory T cells. Cancer vaccines draw attention in the dendritic cell chapter as well as in a focused separate chapter near the end of the book. Cytokines are also discussed extensively with a chapter discussing the role of IFNα as a vaccine adjuvant. Potential therapeutic roles for cytokines of the IL-12 family are the basis of another chapter.

Extensive consideration of technological advances is a focus of the book. These methodologies include genetic engineering of T cells, targeting of T cell co-stimulation, and antibody engineering. Adoption of such technologies has shown marked clinical responses in a variety of cancers. A limitation of the field of adoptive T cell therapy has been the challenge in generally sufficient numbers of antigen- specific T cells. The generation of such antigen - specific CTL using iPSC technology then is a fascinating potential solution as proposed in Chapter 10.

I would like to congratulate the editor, J. Song for bringing together a stellar group from around the world to summarize the current state of the art in the reinvigorated field of cancer immunotherapy.

Thomas P. Loughran
F. Palmer Weber-Smithfield Foods
Professor in Oncology Research
University of Virginia


.Current and Future Application of Artificial Intelligence in Clinical Medicine.
.Thrombosis in Cancer: .
.Frontiers in Clinical Drug Research - Anti-Cancer Agents.
.Head and Neck Cancer: Hallmarks of The Inflammation Ecosystem.